Pharmacokinetics of dexmedetomidine combined with therapeutic hypothermia in a piglet asphyxia model

Acta Anaesthesiologica Scandinavica

Volumn 58, Issue 6, 2014, Pages 733-742

  Ezzati, M ^a   Broad, K ^a   Kawano, G ^a   Faulkner, S ^a   Hassell, J ^a   Fleiss, B ^b,c,d   Gressens, P ^b,c,d   Fierens, I ^a   Rostami, J ^a   Maze, M ^e   Sleigh, J W ^f   Anderson, B ^f   Sanders, R D ^a,g   Robertson, N J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c INSERM   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF AUCKLAND   (New Zealand)

^g UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEXMEDETOMIDINE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRADYCARDIA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; HEART ARREST; HEMODYNAMICS; HYPERTENSION; HYPOTENSION; HYPOXIC ISCHEMIC ENCEPHALOPATHY; INDUCED HYPOTHERMIA; LOADING DRUG DOSE; MALE; NEUROPROTECTION; NONHUMAN; PERINATAL ASPHYXIA; PIGLET; PRIORITY JOURNAL; SEDATION; ANIMAL; BLOOD; COMPLICATION; DISEASE MODEL; HYPOXIA-ISCHEMIA, BRAIN; METABOLIC CLEARANCE RATE; NEWBORN HYPOXIA; NONLINEAR SYSTEM; SWINE;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ANIMALS; ASPHYXIA NEONATORUM; DEXMEDETOMIDINE; DISEASE MODELS, ANIMAL; HYPOTHERMIA, INDUCED; HYPOXIA-ISCHEMIA, BRAIN; MALE; METABOLIC CLEARANCE RATE; NEUROPROTECTIVE AGENTS; NONLINEAR DYNAMICS; SUS SCROFA; SWINE;

EID: 84903124582     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/aas.12318     Document Type: Article

References (47)

1. Kurinczuk J, White-Koning M, Badawi N,. Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy. Early Hum Dev 2010; 86: 329-338.
2. Edwards A, Brocklehurst P, Gunn A, Halliday H, Juszczak E, Levene M, Strohm B, Thoresen M, Whitelaw A, Azzoaprdi D,. Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial data. BMJ 2010; 340: C363.
3. Thoresen M, Satas S, Løberg E, Whitelaw A, Acolet D, Lindgren C, Penrice J, Robertson N, Haug E, Steen PA,. Twenty-four hours of mild hypothermia in unsedated newborn pigs starting after a severe global hypoxic-ischemic insult is not neuroprotective. Pediatr Res 2001; 50: 405-411. (Pubitemid 32801967)
4. Simbruner G, Mittal RA, Rohlmann F, Much R, neo.nEURO.network Trial Participants. Systemic hypothermia after neonatal encephalopathy: outcomes of neo.nEURO.network RC. Pediatrics 2010; 126: e771-778.
5. Kasdorf E, Perlman J,. Hyperthermia, inflammation, and perinatal brain injury. Pediatr Neurol 2013; 49: 8-14.
6. Sanders R, Maze M,. Alpha2-adrenoceptor agonists. Curr Opin Investig Drugs 2007; 8: 25-33.
7. Nelson L, Lu J, Guo T, Saper C, Franks N, Maze M,. The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology 2003; 98: 428-436. (Pubitemid 36592812)
8. Dahmani S, Paris A, Jannier V, Hein L, Rouelle D, Scholz J, Gressens P, Mantz J,. Dexmedetomidine increases hippocampal phosphorylated extracellular signal-regulated protein kinase 1 and 2 content by an alpha 2-adrenoceptor- independent mechanism: evidence for the involvement of imidazoline I1 receptors. Anesthesiology 2008; 108: 457-466. (Pubitemid 351304239)
9. Paris A, Mantz J, Tonner PH, Hein L, Brede M, Gressens P,. The effects of dexmedetomidine on perinatal excitotoxic brain injury are mediated by the alpha2A-adrenoceptor subtype. Anesth Analg 2006; 102: 456-461. (Pubitemid 43152595)
10. Hoffman WE, Kochs E, Werner C, Thomas C, Albrecht RF,. Dexmedetomidine improves neurologic outcome from incomplete ischemia in the rat. Reversal by the alpha 2-adrenergic antagonist atipamezole. Anesthesiology 1991; 75: 328-332.
11. Laudenbach V, Mantz J, Lagercrantz H, Desmonts JM, Evrard P, Gressens P,. Effects of alpha(2)-adrenoceptor agonists on perinatal excitotoxic brain injury: comparison of clonidine and dexmedetomidine. Anesthesiology 2002; 96: 134-141. (Pubitemid 34032493)
12. Mantz J, Josserand J, Hamada S,. Dexmedetomidine: new insights. Eur J Anaesthesiol 2011; 28: 3-6.
13. Ma D, Hossain M, Rajakumaraswamy N, Arshad M, Sanders RD, Franks NP, Maze M,. Dexmedetomidine produces its neuroprotective effect via the alpha 2A-adrenoceptor subtype. Eur J Pharmacol 2004; 502: 87-97. (Pubitemid 39311368)
14. Sanders RD, Xu J, Shu Y, Januszewski A, Halder S, Fidalgo A, Sun P, Hossain M, Ma D, Maze M,. Dexmedetomidine attenuates isoflurane-induced neurocognitive impairment in neonatal rats. Anesthesiology 2009; 110: 1077-1085.
15. Sanders R, Sun P, Patel S, Li M, Maze M, Ma D,. Dexmedetomidine provides cortical neuroprotection: impact on anaesthetic-induced neuroapoptosis in the rat developing brain. Acta Anaesthesiol Scand 2009; 54: 710-716.
16. Sanders R, Hassell J, Davidson A, Robertson NJ, Ma D,. Impact of anaesthetics and surgery on neurodevelopment: an update. Br J Anaesth 2013; 110: i53-72.
17. Taniguchi T, Kidani Y, Kanakura H, Takemoto Y, Yamamoto K,. Effects of dexmedetomidine on mortality rate and inflammatory responses to endotoxin-induced shock in rats. Crit Care Med 2008; 32: 1322-1326.
18. Pandharipande P, Sanders R, Girard T, McGrane S, Thompson J, Shintani A, Herr DL, Maze M, Ely EW, MENDS Investigators. Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial. Crit Care 2010; 14: R38.
19. Azzopardi D, Strohm B, Edwards A, Dyet L, Halliday H, Juszczak E, Kapellou O, Levene M, Marlow N, Porter E, Thoresen M, Whitelaw A, Brocklehurst P, TOBY Study Group. Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med 2009; 361: 1349-1358.
20. Kofke W, Garman R, Stiller R, Rose M, Garman R,. Opioid neurotoxicity: fentanyl dose-response effects in rats. Anesth Analg 1996; 83: 1298-1306. (Pubitemid 26418821)
21. O'Mara K, Gal P, Ransommd J, Wimmermd JJ, Carlosmd R, Dimaguilamd M, Davonzomd C, Smith M,. Successful use of dexmedetomidine for sedation in a 24-week gestational age neonate. Ann Pharmacother 2009; 43: 1707-1713.
22. O'Mara K, Gal P, Wimmer J, Ransom J, Carlos R, Dimaguila M, Davanzo CC, Smith M,. Dexmedetomidine versus standard therapy with fentanyl for sedation in mechanically ventilated premature neonates. J Pediatr Pharmacol Ther 2012; 17: 252-262.
23. Potts A, Warman G, Anderson B,. Dexmedetomidine disposition in children: a population analysis. Paediatr Anaesth 2008; 18: 722-730. (Pubitemid 352000581)
24. Potts A, Anderson B, Warman G, Lerman J, Diaz S, Vilo S,. Dexmedetomidine pharmacokinetics in pediatric intensive care-a pooled analysis. Paediatr Anaesth 2009; 19: 1119-1129.
25. Potts A, Anderson B, Holford N, Vu T, Warman G,. Dexmedetomidine hemodynamics in children after cardiac surgery. Pediatr Anaesth 2010; 20: 425-433.
26. Wong J, Steil G, Curtis M, Papas A, Zurakowski D, Mason K,. Cardiovascular effects of dexmedetomidine sedation in children. Anesth Analg 2012; 114: 193-199.
27. Su F, Hammer G,. Dexmedetomidine: pediatric pharmacology, clinical uses and safety. Expert Opin Drug Saf 2011; 10: 55-66.
28. Mason K, Lerman J,. Dexmedetomidine in children: current knowledge and future applications. Anesth Analg 2011; 113: 1129-1142.
29. Zanelli S, Buck M, Fairchild K,. Physiologic and pharmacologic considerations for hypothermia therapy in neonates. J Perinatol 2011; 31: 377-386.
30. Lorek A, Takei Y, Cady E, Wyatt J, Penrice J, Edwards A, Peebles D, Wylezinska M, Owen-Reece H, Kirkbride V, Reynolds EOR,. Delayed ('secondary') cerebral energy failure after acute hypoxia-ischemia in the newborn piglet: continuous 48-hour studies by phosphorus magnetic resonance spectroscopy. Pediatr Res 1994; 36: 699-706. (Pubitemid 24357779)
31. Beal S, Sheiner L, Boeckmann A,. NONMEM user's guide. San Francisco, CA: Division of Pharmacology, University of California, 1999.
32. Karlsson M, Jonsson E, Wiltse C, Wade J,. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm 1998; 26: 207-246. (Pubitemid 28496599)
33. Holford N,. A size standard for pharmacokinetics. Clin Pharmacokinet 1996; 30: 329-332. (Pubitemid 26177179)
34. Anderson B, Meakin G,. Scaling for size: some implications for paediatric anaesthesia dosing. Paediatr Anaesth 2002; 12: 205-219. (Pubitemid 34264439)
35. Efron B, Tibshirani R,. Bootstrap methods for standard error, confidence intervals and other methods of statistical accuracy. Stat Sci 1986; 1: 54-77.
36. Post T, Freijer J, Ploeger B, Danhof M,. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn 2008; 35: 185-202.
37. Tod M, Jullien V, Pons G,. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 2008; 47: 231-243. (Pubitemid 351367434)
38. Brendel K, Dartois C, Comets E, Lemenuel-Diot A, Laveille C, Tranchand B, Girard P, Laffont CM, Mentre F,. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 2007; 46: 221-234. (Pubitemid 46425648)
39. Karlsson M, Savic R,. Diagnosing model diagnostics. Clin Pharmacol Ther 2007; 82: 17-20. (Pubitemid 46944205)
40. Bergstrand M, Hooker A, Wallin J, Karlsson M,. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011; 13: 143-151.
41. Nunes S, Berg L, Raittinen L, Ahonen H, Laranne J, Lindgren L, Parviainen I, Ruokonen E, Tenhunen J,. Deep sedation with dexmedetomidine in a porcine model does not compromise the viability of free microvascular flap as depicted by microdialysis and tissue oxygen tension. Anesth Analg 2007; 105: 666-672. (Pubitemid 47300841)
42. Tobias J,. Bradycardia during dexmedetomidine and therapeutic hypothermia. J Intensive Care Med 2008; 23: 403-408.
43. Shah P, Riphagen S, Beyene J, Perlman M,. Multiorgan dysfunction in infants with post-asphyxial hypoxic-ischaemic encephalopathy. Arch Dis Child Fetal Neonatal Ed 2004; 89: F152-155. (Pubitemid 38338814)
44. Tortorici M, Kochanek P, Poloyac S,. Effects of hypothermia on drug disposition, metabolism, and response: a focus of hypothermia-mediated alterations on the cytochrome P450 enzyme system. Crit Care Med 2007; 35: 2196-2204. (Pubitemid 47326460)
45. Fukuoka N, Aibiki M, Tsukamoto T, Seki K, Morita S,. Biphasic concentration change during continuous midazolam administration in brain-injured patients undergoing therapeutic moderate hypothermia. Resuscitation 2004; 60: 225-230. (Pubitemid 38230915)
46. Sato K, Kimura T, Nishikawa T, Tobe Y, Masaki Y,. Neuroprotective effects of a combination of dexmedetomidine and hypothermia after incomplete cerebral ischemia in rats. Acta Anaesthesiol Scand 2010; 54: 377-382.
47. Dean JM, George S, Naylor AS, Mallard C, Gunn AJ, Bennet L,. Partial neuroprotection with low-dose infusion of the alpha2-adrenergic receptor agonist clonidine after severe hypoxia in preterm fetal sheep. Neuropharmacology 2008; 55: 166-174.